admin – Page 5045 – Get News Story

Behavior Therapist Shakira Millar Advocates for Increased Access to Early Intervention ABA Therapy

“Every child deserves a chance to thrive, regardless of their circumstances. We need to work together to eliminate these barriers and make ABA therapy accessible to all who need it.” – Shakira Millar, Pembroke Pines, Florida

Shakira Millar is a registered behavior therapist (RBT) certified through the Behavior Analyst Certification Board (BACB) and co-founder of Behavior Change LLC, based in Pembroke Pines, Florida.

Shakira Millar, a dedicated behavior therapist and co-founder of Behavior Change LLC, is advocating for increased access to early intervention Applied Behavior Analysis (ABA) therapy for children with developmental disorders, such as autism spectrum disorder (ASD). With over a decade of experience in ABA therapy, Shakira is urging parents, healthcare professionals, and policymakers to recognize the importance of early intervention to ensure the best possible outcomes for children in need.

“Research has consistently shown that early intervention is crucial for children with developmental delays,” says Shakira Millar. “By starting ABA therapy as early as possible, we can help children build foundational skills, improve communication, and reduce challenging behaviors, setting them up for a more successful future.”

According to the Centers for Disease Control and Prevention (CDC), approximately 1 in 36 children is diagnosed with ASD in the United States. Despite this growing prevalence, many families face barriers to accessing ABA therapy, including long waiting lists, high costs, and limited insurance coverage. Shakira Millar believes that these challenges prevent many children from receiving the support they need during a critical period of development.

“It’s heartbreaking to see families struggle to get the care their children need simply because of financial constraints or a lack of available services,” Shakira emphasizes. “Every child deserves a chance to thrive, regardless of their circumstances. We need to work together to eliminate these barriers and make ABA therapy accessible to all who need it.”

Numerous studies support Shakira’s call for action. Research published in the Journal of Autism and Developmental Disorders found that children who received intensive ABA therapy before the age of 5 showed significant improvements in communication, social skills, and adaptive behavior compared to those who started later or received less intensive treatment.

As part of her advocacy efforts, Shakira Millar is working to raise awareness about the benefits of early intervention by hosting community workshops, speaking at local schools and parent groups, and partnering with organizations that support children with developmental disorders. She aims to provide families with valuable resources, guidance, and encouragement to seek ABA therapy as soon as possible.

“Early intervention can be life-changing,” Shakira states. “The earlier we start, the more progress we can make. My hope is that by raising awareness, we can create a future where every child has access to the support they need to reach their full potential.”

About Shakira Millar

Shakira Millar is a registered behavior therapist (RBT) certified through the Behavior Analyst Certification Board (BACB) and co-founder of Behavior Change LLC, based in Pembroke Pines, Florida. With over a decade of experience in Applied Behavior Analysis (ABA), she is dedicated to helping children and families overcome behavioral challenges and achieve meaningful growth. Shakira has completed her coursework and received her Behavior Analyst certificate from the Florida Institute of Technology (FIT) and is currently preparing to take the Board Certified Behavior Analyst (BCBA) exam, ensuring that she remains compliant with the ethical standards of her field.

Although much of her work focuses on children with developmental disorders, particularly Autism, Shakira believes ABA has much broader applications. She is passionate about advocating for ABA to be recognized as a valuable tool in areas like education, organizational behavior management, sports psychology, and criminal justice. Her compassionate approach, combined with her commitment to ethical practice, has made Shakira a trusted professional in her field, with a vision to expand the reach and impact of ABA therapy across multiple domains.

Media Contact

Shakira Millar

info@shakiramillar.com

https://www.shakiramillar.com/

https://www.behaviorchangellc.com/

Media Contact
Contact Person: Shakira Millar
Email: Send Email
City: Pembroke Pines
State: Florida
Country: United States
Website: https://www.shakiramillar.com/

Dream deeper, wake refreshed: Miracle Plant’s deep sleep natural perfumes are nature’s remedy for restorative sleep

Miracle Plant, a pioneering wellness brand from Australia, has officially launched a Kickstarter campaign to fund its new line of Deep Sleep Natural Perfumes. Available for backers globally, these revolutionary products are designed to transform sleep quality using 100% natural essential oils and have been scientifically validated by Oxford University research, offering an effective alternative to traditional sleep aids.

Miracle Plant’s Deep Sleep Natural Perfumes offer formulations that are designed to cater to different demographics, including women, men, children, and seniors. The clinical trials led by Dr. Sherman Fung demonstrated that 94% of users experienced faster sleep onset, and 97% felt a significant increase in calmness and relaxation. With this proven efficacy, Miracle Plant is set to redefine the natural sleep aid market.

“Our Deep Sleep Natural Perfumes offer a safe, non-addictive solution to the growing issue of sleep disturbances,” said Catherine, Founder of Miracle Plant. “We aim to provide a scientifically-backed alternative that helps people achieve deep, restorative sleep without the drawbacks of traditional sleep aids.”

Compared to more conventional pharmaceutical sleeping aids that are ingested orally, Miracle Plant is sprayed directly on one’s skin, pillow, or bed linens right before going to sleep. The calming aromas work through aromatherapy, engaging the limbic system to promote relaxation and reduce stress. The perfume’s essential oils are absorbed through the skin, enhancing the relaxation effect and promoting restorative sleep.

Miracle Plant’s Key Features:

100% Natural Ingredients: Alcohol-free and GMO-free, the perfumes are made with pure essential oils and are suitable for all ages.
Clinically Proven: Validated using the Pittsburgh Sleep Quality Index (PSQI), the clinical trials showed significant improvements in sleep quality.
Tailored Formulas: Customized blends for different age groups and genders ensure effective results.
Sustainably Produced: Australian-made, adhering to ISO/GMP standards, and each purchase supports reforestation initiatives through Miracle Plant’s partnership with Plant-for-the-Planet.

The Kickstarter campaign offers backers exclusive access to discounted bundles, special edition bottles, and other rewards. Miracle Plant’s goal is to raise funding in order to scale production and expand its reach to new markets in North America and Europe. The campaign also aims to build a community of health-conscious individuals seeking effective, natural sleep solutions.

“We’re excited to bring our innovative sleep aid to a global audience through Kickstarter,” said David Yuen, Co-Founder and Head of Operations at Miracle Plant. “Backers not only get to experience better sleep but also contribute to global reforestation efforts, making each purchase impactful beyond the bedroom.”

For more information or to support the Kickstarter campaign, visit https://www.indiegogo.com/projects/dream-naturally-with-miracle-plant/reft/29942540/refb2

Media Contact
Company Name: Miracle Plant
City: Melbourne
Country: Australia
Website: www.indiegogo.com/projects/dream-naturally-with-miracle-plant/reft/29942540/refb2

Kimberly Advisors Unveils New Exit Planning Resources for Business Owners

The new exit planning eBooks promise a fresh, systematic, and practical approach to exit planning for first-time sellers.

Kimberly Advisors, a boutique investment bank offering M&A advisory services, has unveiled a new exit planning toolkit for business owners. The series of eBooks detailing Kimberly Advisors’ proven exit planning process and comprehensive training for first-time sellers is designed to help owners approach exit planning more systematically.

With these new resources, Kimberly Advisors continues its commitment to helping business owners define what business ownership independence means to them. The eBooks aim to demystify the confusion around valuation, the sale process, time frames, and confidentiality, making it easier for business owners to plan and successfully execute a business exit strategy.

“We are excited to release to the public our new exit planning resources which reflect our dedication to helping business owners maximize their exit value,” said Jeff Davis, the founder and managing director at Kimberly Advisors. “We have designed our eBooks to give owners a crash course on practical exit strategies. These guides are a logical starting point for planning an exit or learning more about the process of selling a private company.”

Besides educating business owners on the process of selling, these eBooks also offer guidance and resources for choosing the best M&A advisor and navigating the due diligence process. Having pioneered a process for working with owners in advance of a transaction to help optimize sale value, Kimberly Advisors’ newly released resources also touch on the evolving role of M&A advisory. The guides emphasize the importance of involving M&A advisors early to build business value. This is aimed at leaving behind the past emphasis of the last-minute transactional relationship between owners and advisors, instead encouraging partnership.

“Moving beyond business owners waiting until they are ready to sell before seeking out council from a competent advisor, these resources stress the importance of early involvement,” added Jeff. “We teach business owners how to proactively improve their value at exit through our exit planning process and the comprehensive education we provide for first-time sellers.”

Kimberly Advisors’ new exit planning resources for business owners are now available on its resource page. For more information, visit https://kimberlyadvisors.com/.

Media Contact
Company Name: Kimberly Advisors
Contact Person: Jeff Davis
Email: Send Email
Country: United States
Website: https://kimberlyadvisors.com/

Dementia Associated With Alzheimer’s Disease Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight’s, “Dementia Associated With Alzheimer’s Disease Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Dementia Associated With Alzheimer’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Dementia Associated With Alzheimer’s Disease Research. Learn more about our innovative pipeline today! @ Dementia Associated With Alzheimer’s Disease Pipeline Outlook

Key Takeaways from the Dementia Associated With Alzheimer’s Disease Pipeline Report

In October 2024:- Karuna Therapeutics- This is a Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female subjects who are aged 55 to 90 years and have mild to severe Alzheimer’s Disease (AD) with moderate to severe psychosis related to AD. The primary objective of the study is to evaluate the efficacy of KarXT compared with placebo in the treatment of subjects with psychosis associated with AD as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.
In October 2024:- Intra-Cellular Therapies, Inc.- A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study of the Efficacy, Safety, and Tolerability of ITI-1284 in Patients With Agitation Associated With Alzheimer’s Dementia. This is a multicenter, randomized, double-blind, placebo-controlled, flexible-dose study of the efficacy, safety, and tolerability of ITI-1284 in patients with agitation associated with Alzheimer’s dementia.
DelveInsight’s Dementia Associated With Alzheimer’s Disease pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Dementia Associated With Alzheimer’s Disease treatment.
The leading Dementia Associated With Alzheimer’s Disease Companies such as BioVie, Karuna Therapeutics, Cassava Sciences, Inc., Cognition Therapeutics, Alector, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., and others.
Promising Dementia Associated with Alzheimer’s disease Therapies such as KarXT, ITI-1284, and others.

Stay informed about the cutting-edge advancements in Dementia Associated With Alzheimer’s Disease treatments. Download for updates and be a part of the revolution in cancer care @ Dementia Associated With Alzheimer’s Disease Clinical Trials Assessment

Dementia Associated With Alzheimer’s Disease Emerging Drugs Profile

NE3107: BioVie

NE3107 is an orally available small molecule with potential anti-inflammatory and insulin-sensitizing properties that can cross the blood-brain barrier. It was originally developed by NeurMedix and acquired by BioVie in April. The experimental molecule works by blocking the activation of two major regulators of inflammatory pathways: extracellular signal regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB). NFκB is activated by amyloid beta and tau — two proteins that form toxic clumps that contribute to Alzheimer’s — and by the pro-inflammatory molecules that it stimulates, leading to chronic inflammation. NE3107 was found to have no immunosuppressive effects and to block ERK- and NF-κB-induced inflammation without suppressing their functions involved in maintaining overall balance, such as insulin signaling and nerve cell growth and survival. Currently, the drug is in Phase III stage of development for the treatment of Alzheimer Disease.

KarXT: Karuna Therapeutics

KarXT, a combination of xanomeline and trospium, is an investigational treatment developed by Karuna Therapeutics, primarily aimed at addressing psychosis associated with Alzheimer’s disease (AD) and schizophrenia. KarXT functions as a muscarinic receptor agonist, specifically targeting the M1 and M4 muscarinic acetylcholine receptors. Xanomeline activates these receptors, which are crucial for cognitive processes such as learning and memory. Trospium, on the other hand, is included to mitigate peripheral side effects associated with xanomeline, such as nausea and vomiting, by preventing its action on muscarinic receptors outside the brain. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Dementia Associated With Alzheimer’s Disease.

Simufilam: Cassava Sciences

Simufilam (formerly known as PTI-125) is an investigational drug being developed by Cassava Sciences. It targets an altered form of filamin A (FLNA), a protein implicated in the disease’s pathology. Unlike traditional Alzheimer’s treatments that focus on clearing amyloid plaques, simufilam works by stabilizing FLNA, thereby potentially reducing neuroinflammation and cognitive decline associated with the disease. Currently, the drug is in the Phase III stage of development to treat Dementia Associated With Alzheimer’s Disease.

CT-1812: Cognition Therapeutics

Cognition Therapeutics isdeveloping CT1812, an oral, brain-penetrant, small molecule therapeutic, which has been shown to protect neurons and synapses by preventing the binding of toxic oligomers. CT1812 acts as a neuroprotective agent both by shielding neurons and synapses from oligomer binding and by preventing oligomers from attaching to synapses in the first place. CT1812 may help mitigate the neurotoxic effects, slowing cognitive decline and progression of Alzheimer’s disease. Currently, the drug is in the Phase II stage of development to treat Alzheimer’s-disease.

CM383: KeyMed Biosciences

CM383 is an investigational drug being developed for the treatment of Alzheimer’s disease. It is a small molecule designed to target the underlying mechanisms of the disease, specifically by modulating the immune response and reducing neuroinflammation, which are key factors in Alzheimer’s pathology. CM383 works by targeting the immune system’s response to amyloid-beta plaques, which are characteristic of Alzheimer’s disease. It aims to enhance the brain’s ability to clear these plaques and improve neuronal health. This approach is distinct from many traditional Alzheimer’s treatments that primarily focus on amyloid plaque reduction or cholinergic modulation. Currently, the drug is in the Phase I stage of development to treat Alzheimer’s-disease.

Learn more about Dementia Associated With Alzheimer’s Disease Drugs opportunities in our groundbreaking Dementia Associated With Alzheimer’s Disease Research and development projects @ Dementia Associated With Alzheimer’s Disease Unmet Needs

Dementia Associated With Alzheimer’s Disease Companies

BioVie, Karuna Therapeutics, Cassava Sciences, Inc., Cognition Therapeutics, Alector, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., and others

Dementia Associated With Alzheimer’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Dementia Associated With Alzheimer’s Disease Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Discover the latest advancements in Dementia Associated With Alzheimer’s Disease treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Dementia Associated With Alzheimer’s Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Dementia Associated With Alzheimer’s Disease Pipeline Report

Coverage- Global
Dementia Associated With Alzheimer’s Disease Companies- BioVie, Karuna Therapeutics, Cassava Sciences, Inc., Cognition Therapeutics, Alector, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., and others.
Dementia Associated with Alzheimer’s disease Therapies- KarXT, ITI-1284, and others.
Dementia Associated With Alzheimer’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Dementia Associated With Alzheimer’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Dementia Associated With Alzheimer’s Disease Pipeline on our website @ Dementia Associated With Alzheimer’s Disease Emerging Drugs and Companies

Table of Content

Introduction
Executive Summary
Dementia Associated With Alzheimer’s Disease: Overview
Pipeline Therapeutics
Therapeutic Assessment
Dementia Associated With Alzheimer’s Disease– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
NE3107: BioVie
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
CT-1812: Cognition Therapeutics
Early Stage Products (Phase I)
CM383: KeyMed Biosciences
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Dementia Associated With Alzheimer’s Disease Key Companies
Dementia Associated With Alzheimer’s Disease Key Products
Dementia Associated With Alzheimer’s Disease- Unmet Needs
Dementia Associated With Alzheimer’s Disease- Market Drivers and Barriers
Dementia Associated With Alzheimer’s Disease- Future Perspectives and Conclusion
Dementia Associated With Alzheimer’s Disease Analyst Views
Dementia Associated With Alzheimer’s Disease Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dementia Associated With Alzheimer’s Disease Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

Respiratory Syncytial Virus Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | GSK, MedImmune, ReViral, Pfizer, Sanofi, BioComo, Merck

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Respiratory Syncytial Virus pipeline constitutes 50+ key companies continuously working towards developing 50+ Respiratory Syncytial Virus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Respiratory Syncytial Virus Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Respiratory Syncytial Virus Market.

The Respiratory Syncytial Virus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Respiratory Syncytial Virus Pipeline Report:

Companies across the globe are diligently working toward developing novel Respiratory Syncytial Virus treatment therapies with a considerable amount of success over the years.
Respiratory Syncytial Virus companies working in the treatment market are GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Atriva Therapeutics, Calder Biosciences Inc, Cidara Therapeutics Inc, Clover Biopharmaceuticals, Curevac AG, Enyo Pharma SA, HanaVax Inc., Icosavax Inc, IDBiologics Inc, Pneumagen Ltd, Riboscience LLC, Signia Therapeutics, and others, are developing therapies for the Respiratory Syncytial Virus treatment

Emerging Respiratory Syncytial Virus therapies in the different phases of clinical trials are- Nirsevimab (MEDI-8897), Sisunatovir, RSV F protein vaccine, Novavax, Combination seasonal influenza RSV nanoparticle vaccine, NanoFlu/NVX CoV 2373/RSV, RSVpreF, SP 0125, BC-0004, GSK 3888550A, DPX RSV Vaccine, AR 201, ASCENIV, EDP 938, MK 1654, Rilematovir, GSK 3003891A, JNJ 64400141, Ziresovir, JNJ 64213175, MV-012-968, ALS-008176, CodaVax-RSV, BARS13, MVA-BN-RSV, mRNA-1345, V-306, ALVR106, AR-201, AT-889, ATR-002, IVX-121, RBS-3149, and others are expected to have a significant impact on the Respiratory Syncytial Virus market in the coming years.
In October 2024, GSK has released encouraging results from its Phase III AReSVi-006 clinical trial of Arexvy, its RSV vaccine designed to prevent lower respiratory tract disease (LRTD) over three RSV seasons. The trial included about 25,000 participants across 17 countries and focused on adults aged 60 and older, particularly those at higher risk. The primary objective of the trial was to evaluate the vaccine’s efficacy against RSV-LRTD following one RSV season.
In July 2024, MSD (Merck & Co) announced encouraging topline results from its Phase IIb/III MK-1654-004 clinical trial evaluating clesrovimab as a preventive treatment for respiratory syncytial virus (RSV) in infants. This double-blind, randomized, placebo-controlled study aimed to examine the safety and efficacy of clesrovimab. Participants, which included healthy preterm and full-term infants, were randomly assigned to receive either a single dose of clesrovimab or a placebo.
In May 2023, Arexvy is an innovative adjuvanted vaccine designed to combat respiratory syncytial virus (RSV), a significant cause of lower respiratory tract disease (LRTD) in individuals aged 60 and older. Developed by GlaxoSmithKline (GSK), a UK-based pharmaceutical company, Arexvy contains RSVPreF3, a genetically engineered protein derived from the virus, coupled with AS01E, GSK’s exclusive adjuvant.
In May 2023, In order to treat respiratory syncytial virus (RSV) infection, Ascletis Pharma Inc. revealed that the China National Medical Products Administration (“NMPA”) has authorised a Phase IIa clinical trial for ASC10

Respiratory Syncytial Virus Overview

Respiratory Syncytial Virus (RSV) is a common respiratory virus that primarily affects the lungs and respiratory tract, often causing mild, cold-like symptoms. While it usually resolves on its own in healthy adults, RSV can be severe in infants, young children, and older adults, potentially leading to bronchiolitis and pneumonia. RSV spreads easily through droplets when an infected person coughs or sneezes, as well as through direct contact with surfaces. Symptoms include a runny nose, coughing, fever, and wheezing. In high-risk cases, treatment may involve supportive care, and prevention strategies include hand hygiene and, for vulnerable populations, protective vaccines.

Get a Free Sample PDF Report to know more about Respiratory Syncytial Virus Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-pipeline-insight

Emerging Respiratory Syncytial Virus Drugs Under Different Phases of Clinical Development Include:

Nirsevimab (MEDI-8897): MedImmune
Sisunatovir: ReViral
MVA-BN-RSV Vaccine: Bavarian Nordic
RSVpreF (PF-06928316): Pfizer
VAC 18193 (Ad26.RSV.preF): Janssen
mRNA-1345: ModernaTX, Inc
GSK3844766A: GlaxoSmithKline
RSVPreF3: GlaxoSmithKline
STR-V003/Placebo: Starna Therapeutics
TNM001: Zhuhai Trinomab Pharma
Sisunatovir: Pfizer
RSVt Vaccine: Sanofi
Deuremidevir Hydrobromide for Suspension: Vigonvita Life Sciences
Nirsevimab: AstraZeneca
TNM001: Zhuhai Trinomab Pharma
Clesrovimab: Merck Sharp & Dohme LLC
EDP-938: Enanta Pharmaceuticals

Route of Administration

Respiratory Syncytial Virus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical.
Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type

Respiratory Syncytial Virus Pipeline Therapeutics Assessment

Respiratory Syncytial Virus Assessment by Product Type
Respiratory Syncytial Virus By Stage and Product Type
Respiratory Syncytial Virus Assessment by Route of Administration
Respiratory Syncytial Virus By Stage and Route of Administration
Respiratory Syncytial Virus Assessment by Molecule Type
Respiratory Syncytial Virus by Stage and Molecule Type

DelveInsight’s Respiratory Syncytial Virus Report covers around 50+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Respiratory Syncytial Virus product details are provided in the report. Download the Respiratory Syncytial Virus pipeline report to learn more about the emerging Respiratory Syncytial Virus therapies

Respiratory Syncytial Virus Pipeline Analysis:

The Respiratory Syncytial Virus pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Respiratory Syncytial Virus with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Respiratory Syncytial Virus Treatment.
Respiratory Syncytial Virus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Respiratory Syncytial Virus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Respiratory Syncytial Virus market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Respiratory Syncytial Virus drugs and therapies

Respiratory Syncytial Virus Pipeline Market Drivers

Rising government funding for treatment and proactive government initiatives generates profitable opportunities, the growing disease rate, advent of Targeted Therapies are some of the important factors that are fueling the Respiratory Syncytial Virus Market.

Respiratory Syncytial Virus Pipeline Market Barriers

However, lack of adequate diagnostic facilities for RSV, limited awareness among parents and other factors are creating obstacles in the Respiratory Syncytial Virus Market growth.

Scope of Respiratory Syncytial Virus Pipeline Drug Insight

Coverage: Global
Key Respiratory Syncytial Virus Companies: GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Atriva Therapeutics, Calder Biosciences Inc, Cidara Therapeutics Inc, Clover Biopharmaceuticals, Curevac AG, Enyo Pharma SA, HanaVax Inc., Icosavax Inc, IDBiologics Inc, Pneumagen Ltd, Riboscience LLC, Signia Therapeutics, and others
Key Respiratory Syncytial Virus Therapies: Nirsevimab (MEDI-8897), Sisunatovir, RSV F protein vaccine, Novavax, Combination seasonal influenza RSV nanoparticle vaccine, NanoFlu/NVX CoV 2373/RSV, RSVpreF, SP 0125, BC-0004, GSK 3888550A, DPX RSV Vaccine, AR 201, ASCENIV, EDP 938, MK 1654, Rilematovir, GSK 3003891A, JNJ 64400141, Ziresovir, JNJ 64213175, MV-012-968, ALS-008176, CodaVax-RSV, BARS13, MVA-BN-RSV, mRNA-1345, V-306, ALVR106, AR-201, AT-889, ATR-002, IVX-121, RBS-3149, and others
Respiratory Syncytial Virus Therapeutic Assessment: Respiratory Syncytial Virus current marketed and Respiratory Syncytial Virus emerging therapies
Respiratory Syncytial Virus Market Dynamics: Respiratory Syncytial Virus market drivers and Respiratory Syncytial Virus market barriers

Request for Sample PDF Report for Respiratory Syncytial Virus Pipeline Assessment and clinical trials

Table of Contents

1	Respiratory Syncytial Virus Report Introduction
2	Respiratory Syncytial Virus Executive Summary
3	Respiratory Syncytial Virus Overview
4	Respiratory Syncytial Virus- Analytical Perspective In-depth Commercial Assessment
5	Respiratory Syncytial Virus Pipeline Therapeutics
6	Respiratory Syncytial Virus Late Stage Products (Phase II/III)
7	Respiratory Syncytial Virus Mid Stage Products (Phase II)
8	Respiratory Syncytial Virus Early Stage Products (Phase I)
9	Respiratory Syncytial Virus Preclinical Stage Products
10	Respiratory Syncytial Virus Therapeutics Assessment
11	Respiratory Syncytial Virus Inactive Products
12	Company-University Collaborations (Licensing/Partnering) Analysis
13	Respiratory Syncytial Virus Key Companies
14	Respiratory Syncytial Virus Key Products
15	Respiratory Syncytial Virus Unmet Needs
16	Respiratory Syncytial Virus Market Drivers and Barriers
17	Respiratory Syncytial Virus Future Perspectives and Conclusion
18	Respiratory Syncytial Virus Analyst Views
19	Appendix
20	About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Respiratory Syncytial Virus Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | GSK, MedImmune, ReViral, Pfizer, Sanofi, BioComo, Merck

AI Ease Unveils Groundbreaking Updates to Its Free AI-Powered Photo Enhancer

Imagine taking your photos from ordinary to extraordinary in seconds, without spending a dime. AI Ease, a leader in AI-driven photo editing, announces major enhancements to its Photo Enhancer tool, including the addition of specialized AI models, advanced upscaling technology, and faster image processing. These updates provide users with professional-grade photo enhancements—all available for free.

AI Ease, known for offering powerful, AI-driven photo editing tools, is excited to reveal a significant upgrade to its free Photo Enhancer tool, transforming the way users improve image quality and resolution. This major update introduces three cutting-edge AI models designed to cater to specific enhancement needs: General, Art Image, and Restore & Colorize. Additionally, AI Ease has integrated advanced upscaling technology, now offering 2x and 4x resolution improvements, along with batch processing capabilities, making it easier and faster to enhance multiple photos at once.

With these groundbreaking updates, AI Ease reaffirms its mission: making professional-grade photo editing accessible to everyone, regardless of budget. Whether you’re a social media enthusiast, a small business owner, or a professional photographer, AI Ease’s free tools empower you to create stunning visuals without the hefty price tag

Introducing Three Premium AI Models for Enhanced Photo Quality

AI Ease has rolled out three new, specialized AI models to take your photos to the next level. Whether you’re enhancing everyday pictures, perfecting anime art, or restoring old, damaged photos, these AI models are designed to cater to your specific needs

· General Model:

This model is optimized for enhancing the overall quality of realistic images, such as everyday photos, landscapes, portraits, and commercial images. It improves clarity, color balance, and sharpness, ensuring that the images retain their natural appeal while achieving higher resolution and detail.

· Art Image Model:

Created specifically for anime-style images, AI-generated art, and illustrations, the Art Image model preserves the unique aesthetic elements of such visuals. Whether it’s smooth color transitions, delicate line work, or stylized features, this model ensures that anime images or artwork are enhanced without losing their original charm or vibrancy.

· Restore & Colorize Model:

This model is perfect for breathing new life into old or damaged photographs. By restoring faded or damaged images and adding natural-looking colors to black-and-white photos, the Restore & Colorize model helps preserve precious memories. Users can now easily revive family albums, historical photos, and treasured memories with stunning results.

AI-Powered Upscaling Technology for Crystal-Clear High Definition

One of the standout features in this update is the integration of AI upscaling technology, allowing users to enlarge their images without compromising quality. AI Ease now offers 2x and 4x upscaling options, enabling users to increase the resolution of their images while maintaining sharpness and fine details. Whether users are preparing images for large-format printing, marketing materials, or just enhancing personal photos, this tool guarantees high-definition results, even when images are significantly enlarged. Whether you’re an e-commerce seller enhancing product photos for your website, a photographer restoring treasured family albums, or a social media creator looking for that picture-perfect post, AI Ease’s tools help you produce crisp, high-resolution images that stand out.

Batch Processing for High-Efficiency Workflows

In addition to the new AI models and upscaling options, AI Ease introduces batch upload capabilities in the updated Photo Enhancer. Users can now upload and enhance several photos simultaneously, making it easier for professionals and businesses to process large volumes of images quickly. Whether you’re an e-commerce business looking to enhance product images, a marketer creating content, or a photographer working on a large project, batch processing ensures that your workflow remains efficient and seamless. By speeding up the enhancement process, AI Ease saves users valuable time without sacrificing the quality of the final output. With batch processing, you’ll experience a more efficient workflow that saves time without compromising on quality. Whether you’re working on a few photos or hundreds, AI Ease ensures that each one gets the same professional-level enhancement, freeing up your time for what really matters.

Faster Enhancement Time: Processing in Just Seconds

With this latest update, AI Ease has significantly reduced the time it takes to enhance photos. What used to take minutes can now be done in just seconds. This improvement allows users to experience real-time editing results, ensuring a smoother and more efficient experience. Whether you’re enhancing a single image or processing a batch of photos, AI Ease’s optimized performance guarantees swift and satisfying results.

Delivering Exceptional, Professional-Grade Results

AI Ease’s Photo Enhancer tool leverages the latest advancements in artificial intelligence to deliver professional-grade results that meet the needs of various users, from casual photographers to professionals. By intelligently enhancing image quality, adjusting lighting and color balance, and increasing resolution without losing clarity, the tool allows users to transform ordinary photos into stunning, high-quality visuals.

Explore a Full Suite of Free AI Tools from AI Ease

In addition to the enhanced Photo Enhancer, AI Ease offers a wide range of free, AI-powered tools designed to simplify the photo editing process. These tools are perfect for users looking to elevate their creative projects or improve their professional content:

· AI Headshot Generator: Quickly create professional or creative headshots, avatars, and profile pictures. Ideal for social media profiles, resumes, business cards, and more.

· Passport Photo Maker: Instantly generate passport photos that meet the official requirements for various countries in just seconds.

· Background Remover: Effortlessly remove backgrounds from images and replace them with custom backgrounds or stunning backdrops for a polished look.

· Photo Restoration: Bring old and damaged photos back to life by repairing imperfections such as scratches, stains, and discoloration.

· AI Image Enlarger: Increase image resolution for enhanced clarity, perfect for printing or digital use.

· AI Object Remover: Easily remove unwanted objects or distractions from your photos for a clean, professional result.

· AI Watermark Remover: Seamlessly remove watermarks from images without affecting their quality.

· AI Filters: Transform your photos with creative filters, including cartoon, anime, pixel art, watercolor, and more, offering a fun and artistic touch to your images. It’s a quick way to give your images a unique touch that stands out, whether for personal projects or social media content.

About AI Ease

AI Ease is a cutting-edge platform offering a comprehensive suite of free AI-powered photo editing tools designed to simplify and enhance the photo editing experience. The platform’s mission is to make advanced AI technology accessible to everyone, whether for personal use or professional projects. With its user-friendly interface and high-quality results, AI Ease caters to a wide range of users, from casual photographers to professional designers. All tools are available without sign-up or fees, ensuring a seamless, hassle-free experience for all.

For more information, visit www.aiease.ai.

Media Contact
Company Name: AI Ease
Contact Person: Jade W
Email: Send Email
Country: China
Website: https://www.aiease.ai/

Unveiling the Authentic Beauty of Le Marche: The True Colors of Italy Experience

Discover Italy’s Hidden Gem with Exclusive, Immersive Tours in Le Marche

True Colors of Italy is proud to introduce a range of private, themed, exclusive, boutique tours dedicated to the discovery of the intoxicating charm of Le Marche, one of Italy’s best-kept secrets. Tucked between the Apennine Mountains and the Adriatic Sea, Le Marche fascinates with its rolling hills, medieval villages, and pristine beaches. It offers travelers the chance to behold Italy’s authentic beauty in its most untouched form.

These bespoke tours cater to the needs of all those who would like to venture beyond the beaten tracks of tourism. Each tour is a blend of culture and history, added to some delectable food, steeping them deep into the rich heritage of this region. From private tours in the vineyards, to sailing down the Adriatic coast, from castles of old to meeting artisans in their workshops, every tour showcases the real essence of this ‘Hidden Italian Paradise’.

“Our goal is to reveal the true colors of Le Marche,” says Fred Macaluso, founder of True Colors of Italy. “This region is brimming with natural beauty, tradition, and culinary excellence that most travelers overlook. We want to create unforgettable experiences that leave a lasting impression of Italy’s untamed allure.”

Wine lovers, history enthusiasts, or those who love adventure: True Colors of Italy offers the right tour for many tastes. Whether on a romantic getaway or a family adventure, they will appreciate the personal time that is spent in these private tours and developing a real connection to this region.

Highlights of The True Colors of Italy Experience:

– Private Vineyard Tours: Savor Le Marche’s finest wines with exclusive tastings and behind-the-scenes tours of family-run vineyards.

– Sailing Adventures: Explore the Adriatic Sea on a private sailboat, taking in the coastal beauty from a new perspective.

– Castle Exploration: Step back in time with guided tours of medieval castles and fortified towns that tell the story of Italy’s storied past.

– Artisan Workshops: Experience hands-on crafting sessions with local artisans, offering a closer look at traditional arts, crafts, and cuisine.

True Colors of Italy invites travelers to discover the heart and soul of Le Marche, experiencing Italy in a way that’s both personal and profound.

For more information about the themed boutique tours and upcoming itineraries, visit truecolorsofitaly.com or contact Fred Macaluso.

About True Colors of Italy

True Colors of Italy offers bespoke, immersive tours of Italy’s Le Marche region, focusing on authentic experiences that celebrate the area’s natural beauty, culture, and cuisine. Through intimate group sizes and expertly curated itineraries, the company aims to provide travelers with a unique and unforgettable journey.

Media Contact
Company Name: True Colors of Italy
Contact Person: Fred Macaluso
Email: Send Email
Phone: (475) 296 5220
Country: United States
Website: https://truecolorsofitaly.com

Web Rank Digital Redefines SEO To Become One of the Most Trusted Marketing Agencies in the Industry

The platform has developed a name for providing over-the-top SEO and other marketing services to increase the digital presence of various corporations. With this development, Web Rank Digital aims to strengthen its position and adapt to the evolving market needs.

Web Rank Digital is a digital marketing agency with over 15 years of experience. They specialize in design, business marketing, and development, and have garnered over 360 clients. This level of marketing expertise has shown itself in the $6 million revenue generated for its customers.

Premium Services Offered To The Clients

With over 10 services provided under 1 marketing platform, Web Rank Digital aims to develop a holistic view of its clients’ businesses. It has completely revolutionized local SEO strategies to boost clients’ visibility.

To attract high-quality leads, it will also maximize ROI with paid search campaigns as the company has set out to become a reliable agency that boosts conversions.

Another service provided is the maintenance of social media pages for digital presence and visibility. With brand reputation management, Web Rank Digital continues its commitment to innovation by offering a link-building platform that empowers businesses and individuals to boost their site audience by quoting reputable sources.

Developing Websites for Business Owners

The platform also includes developing websites for clients, allowing customers to find and reach various sites. With its tailor-made website for every business, it sets a new standard for the marketing industry.

Experts at the corporation will develop websites integrating UI/UX to engage visitors aesthetically and practically through web design. To fulfill the mission of Web Rank Digital, it specializes in creating visual content that will capture the attention of the target audience.

With the latest brand development of introducing on-page optimization on websites to enhance creative elements, it is set to build on its analytics and reporting metrics as it continues to provide simple yet effective performance reports of the website.

The Working Process That Translates To Customer Success

To remain transparent and trusted throughout the process, Web Rank Digital has outlined an easy process to ensure the client’s website is tailored to their goals. This has allowed the organization to become a top-tier marketing agency trusted by many clients.

To emphasize the custom-made websites for higher outreach, Patrick Rhyne, a company representative commented, “Climbing to the top, one site at a time.”

Web Rank Digital believes that the foundation of successful marketing campaigns is an understanding of the client’s business goals. It explores one business, at a time marking its deep commitment and excellence to the customers.

They adopt a client-centric approach to create a unique plan and use strategies to improve various campaigns as a broader platform mission is to constantly innovate and meet the needs of its growing customer base.

For more information about Web Rank Digital and its successful marketing campaigns, please refer to the details below.

Media Contact
Company Name: Web Rank Digital
Contact Person: Patrick Rhyne
Email: Send Email
Phone: 8777265871
Country: United States
Website: https://www.webrankdigital.com/

The Era of Female AI Founders: Breaking Barriers and Leading the Future of Tech

A significant shift is underway as more women rise to leadership roles in artificial intelligence (AI). Despite persistent underrepresentation, a new wave of female founders is breaking barriers and redefining the industry’s landscape, driving innovation and fostering a more inclusive tech environment.

According to statistics from Deloitte, women in AI and computer science doctorate programs constitute only 25% of total students. Forbes reports that women account for approximately 25% of the tech workforce, and female founders secure just 22% of venture capital investments. These figures highlight the ongoing challenges women face in the tech sector. However, the emergence of pioneering women in AI offers a beacon of hope for a more inclusive and diverse future.

1 – Esranur Kaygin – CEO and Founder Hirize AI

Despite these barriers, a new wave of female AI founders is emerging. Pioneers like Mira Murati, former CTO of OpenAI, have set the stage for others to follow. Murati, known for her role in developing ChatGPT, broke into a male-dominated field and proved that gender is no barrier to success in AI. Her leadership changed perceptions, inspiring more women to enter the AI space.

One of these women is Esranur Kaygin founder of Hirize. Her company is transforming document intelligence with AI. With over a decade of experience, including seven years in venture capital. But rather than staying on the investor side, Esranur was drawn back to building and founded Hirize on the premise that AI’s potential can only be fully realized with precise and reliable data. “If your data isn’t clean, your AI won’t work,” Kaygin explains. Under her leadership, Hirize has become a standout in the competitive AI space by focusing on achieving research based 95% accuracy in document parsing.

2 – Kaygin during COS (capital on stage) in Amsterdam – The Netherlands

Hirize’s mission is simple but powerful: to provide enterprises and SaaS platforms with tools to manage and digest large amounts of unstructured document data. Hirize’s solutions include advanced parsers for invoices and resumes, AI agents to automate complex workflows, and an enterprise search solution that empowers businesses to retrieve and leverage critical data quickly. These innovations enable companies to make faster, more accurate, and informed decisions by automating document workflows.

3 Hirize Dashboard – product page

Kaygin’s leadership and vision earned her company recognition, including acceptance into the Techstars accelerator, and the prestigious NVIDIA inception accelerator program.

The rise of women like Mira Murati and Esranur Kaygin signals a transformative shift in the tech industry. While underrepresentation remains a challenge, the success of female founders in AI suggests change is on the horizon. Women are no longer on the fringes of this revolution; they are leading it.

4 – Kaygin is of Dutch descent, and she studied economics at NYU

Kaygin hopes to serve as a role model for young girls and women aspiring to join the tech revolution. She emphasizes the importance of early engagement in STEM (Science, Technology, Engineering, Mathematics) projects, stating, “Participating in STEM activities and pursuing tech interests is crucial for young girls, who are statistically underrepresented in these fields. By nurturing their passion for technology from an early age, we can empower girls to become future leaders in tech,” she says.

As more women enter AI, the industry benefits from fresh perspectives and inclusive technology. Female founders like Esranur Kaygin are proving that diversity in leadership leads to better problem-solving. With role models like Murati and founders like Esranur, this is just the beginning of a new era in tech.

Learn more about Hirize by visiting https://hirize.ai/

ABOUT HIRIZE

Hirize is an AI-driven platform transforming document intelligence for enterprises and SaaS platforms. Advanced parsers for invoices and resumes, AI agents to automate complex workflows, and powerful enterprise search solutions enable businesses to manage unstructured document data efficiently, making faster and more informed decisions.

Media Contact
Company Name: Hirize
Contact Person: Esranur Kaygin, Founder
Email: Send Email
Country: United States
Website: https://hirize.ai/

Jazeel Perfumes: Voted Number One Oud Perfume in the World

Founded in 2018, Jazeel Perfumes has rapidly ascended to prominence in the luxury fragrance market, proudly earning the title of the number one oud perfume house in the world. This remarkable achievement reﬂects the brand’s dedication to quality, craftsmanship, and a deep appreciation for the art of perfumery.

A Legacy Rooted in Passion

The journey of Jazeel Perfumes is rooted in the passion of its founder, Ali Alzaabi, whose lifelong love for fragrances inspired him to create a brand that celebrates the richness of traditional oud. His vision was clear: to craft exquisite perfumes that resonate with individuals seeking both authenticity and sophistication. Each Jazeel fragrance embodies this legacy, combining ancient traditions with modern elegance.

Global Appeal

From its heart in the UAE, Jazeel has expanded its reach to countries across the globe, including Australia, Belgium, France, Germany, Italy, and the UK. This global appeal showcases the brand’s ability to connect with diverse audiences, attracting fragrance enthusiasts who appreciate the depth and quality of Jazeel’s offerings. Each scent tells a story, inviting wearers to embark on a sensory journey that transcends geographical boundaries.

Signature Fragrances

Jazeel’s signature fragrances, such as Millenium Star (https://jazeelperfumes.com/collections/imperial-collection) and Ghala (https://jazeelperfumes.com/collections/our-collection), have captivated audiences with their rich, multi-layered aromas. These best-selling scents embody the essence of Jazeel’s identity: sophisticated, bold, and utterly unforgettable. Each bottle represents the brand’s commitment to craftsmanship, offering a unique olfactory experience that lingers long after application.

Poetry in Every Bottle

What truly sets Jazeel apart is its ability to infuse poetry and emotion into every fragrance. Inspired by the timeless works of renowned poet Nizar Qabbani, Jazeel’s perfumes evoke feelings of love, passion, and nostalgia. Each scent is designed not just to be worn but to resonate deeply with the wearer, making it a cherished part of their personal story. The Love Collection, inﬂuenced by Qabbani’s romantic verses, ensures that every bottle evokes profound emotions, connecting with consumers on a personal level.

Voted Number One Oud perfume in the World

The prestigious recognition as the number one oud perfume house in the world is not just an accolade; it is a testament to Jazeel’s unwavering commitment to excellence. This honor reﬂects the brand’s relentless pursuit of quality, innovation, and a deep understanding of the fragrance market. As Jazeel continues to evolve, it remains dedicated to crafting unique, memorable experiences for fragrance lovers worldwide.

Jazeel Perfumes has carved out a distinctive niche in the luxury oud market, characterized by its commitment to quality, craftsmanship, and innovation. As the brand continues to evolve, it invites fragrance lovers to explore the rich tapestry of scents that reﬂect both tradition and modernity. With a legacy of excellence and a vision for the future, Jazeel Perfumes stands poised to redeﬁne the landscape of luxury perfumery, enchanting customers around the globe.

More info: https://jazeelperfumes.com/

Media Contact
Company Name: Jazeel
Contact Person: Jazeel
Email: Send Email
Country: United Arab Emirates
Website: https://jazeelperfumes.com/